2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1040

Combined High-Resolution Single Photon Emission Computed Tomography and Magnetic Resonance Imaging for Therapy Monitoring in Rheumatoid Arthritis
Abstract Number: 92

Combined Response Index in Diffuse Systemic Sclerosis (CRISS)—Which External Anchors to Use When Developing the Index? Baseline Analysis
Abstract Number: 105

Combined Synovial and Structural Ultrasound Score for the Diagnosis of RA
Abstract Number: 1636

Commensal Gut-Derived Bacteria As Therapy for Systemic Autoimmune Disease
Abstract Number: 2183

Common Features in Lymphoproliferative Complications in the Course of Primary Sjögren’s Syndrome: Results From a Multicenter Cohort of 1170 Patients
Abstract Number: 77

Comorbid Conditions Do Not Explain Divergent Patient Assessments of Disease Activity and Global Health in Patients with Rheumatoid Arthritis
Abstract Number: 2171

Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Abstract Number: 1531

Comparative Proteomic Analysis of Neutrophils Between Microscopic Polyangiitis and Granulomatosis with Polyangiitis
Abstract Number: 1983

Comparative Risk of Fracture in Men and Women with Human Immunodeficiency Virus
Abstract Number: 953

Comparative Symptom Severity of Patients Satisfying Chronic Widespread Pain and Fibromyalgia Criteria
Abstract Number: 1814

Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Abstract Number: 110

Comparing Palmar and Dorsal Ultrasound Assessment of Small Joint Synovitis in Rheumatoid Arthritis: Dorsal Greyscale Mode Yields Significantly Better Concordance with Power Doppler
Abstract Number: 604

Comparing the ACR and the SLICC Criteria for the Classification of SLE Patients Using Data from an Existing Multi-Ethnic Cohort
Abstract Number: 547

Comparison and Validation of Screening Questionnaires for Psoriatic Arthritis in Patients with Psoriasis
Abstract Number: 1126

Comparison between Osteoartritis Initiative and CHECK study (Cohort Hip & Cohort Knee); Development of pain and function during 4 years follow-up

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].